Clinical Trial Update: Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating Eylea (aflibercept) and Lucentis (ranibizumab) for macular edema due to branch retinal vein occlusion. The trial status is compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Branch Retinal Vein Occlusion
• Macular Edema

Drugs mentioned

• EYLEA (Aflibercept)
• Lucentis (ranibizumab)

Snippet

Sponsor: St. Erik Eye Hospital | Conditions: Branch Retinal Vein Occlusion with Macular Edema | Phase 4 | Status: COMPLETED